About Tripartite motif-containing protein 49D
Tripartite motif-containing protein 49D (TRIM49D1) is a protein
from Homo sapiens identified by UniProt accession
C9J1S8, 452 residues long.
MolForge cross-references it against 0 known binders and
9 disease associations.
Target properties
| Protein name | Tripartite motif-containing protein 49D |
| UniProt accession | C9J1S8 |
| Gene | TRIM49D1 |
| Organism | Homo sapiens |
| Length | 452 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (9)
Diseases linked to this target (Open Targets).
- basophil count · score 0.36
- basophil percentage of granulocytes · score 0.06
- smoking status measurement · score 0.04
- basophil percentage of leukocytes · score 0.04
- adolescent idiopathic scoliosis · score 0.03
- pulse pressure measurement · score 0.03
- homocysteine measurement · score 0.03
- sunburn · score 0.03
- hair colour measurement · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-C9J1S8-F1 | alphafold | PREDICTED | 85.68 | — |
Amino-acid sequence (452 residues)
MNSGISQVFQ RELTCPICLN YFIDPVTIDC GHSFCRPCFY LNWQDIPILT QCFECLKTTQ QRNLKTNIRL KKMASRARKA SLWLFLSSEE QMCGTHRETK KIFCEVDRSL LCLLCSSSLE HRYHRHCPAE WAAEEHREKL LKKMQSLWEK VCENQRNLNV ETTRISHWKD YVNVRLEAIR AEYQKMPAFH HEEEKHNLEM LKKKGKDIFH RLHLSKAKMA HRREILRGTY AELMKMCHKP DVELLQAFGD ILHRSESVLL HMPQPLNLEL RAGPITGLRD RLNQFRVDIT LPHNEANSHI FRRGDLRSIC IGCDRQNAPH ITATPTSFLA WGAQTFTSGK YYWEVHVGDS WNWAFGVCNK YWKGTNQNGN IHGEEGLFSL GCVKNDIQCS LFTTSPLTLQ YVPRPTNHVG LFLDCEARTV SFVDVNQSSP IHTIPNCSFS PPLRPIFCCV HL
Explore Tripartite motif-containing protein 49D with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets